|
Clinical Information
- Description
| Description (as of 4/2007): |
Close |
|
Adalimumab is a humanized recombinant monoclonal antibody against tumor tumor necrosis factor.
|
- ACP Journal Club
- PIER
| PIER (as of 3/28/2007): |
Close |
From: Crohn's Disease - Drug Therapy 
| (© - subscription required) |
Authors: Hanauer, SB; Sparrow, MP |
|
|
Consider drug treatment options for moderate-to-severe disease
• Use adalimumab subcutaneously with an initial induction dose of 140 mg (four injections) then 80 mg (two injections) in 2 weeks, then 40 mg (one injection) every 2 weeks in patients refractory to AZA or MTX or for those in whom infliximab failed
|
- UpToDate
| UpToDate (as of 12/4/2006): |
Close |
From: Investigational therapies in the medical management of Crohn's disease
| (© - subscription required) |
Authors: Korzenik JR |
|
|
Pilot studies suggest that it [adalimumab] may also be effective in Crohn's disease including those who have lost responsiveness to infliximab. Most of the antibodies that develop against infliximab are presumably directed towards the murine portion of the molecule and will not cross react with the fully human adalimumab.
|
Patient Information
Regulatory
|
Infliximab
- Description
| Description (as of 4/2007): |
Close |
|
Infliximab is a chimeric mouse/human recombinant monoclonal antibody against tumor necrosis factor.
|
- Clinical Information
- ACP Journal Club
- PIER
| PIER (as of 3/28/2007): |
Close |
From: Crohn's Disease - Drug Therapy
| (© - subscription required) |
Authors: Hanauer SB et al |
|
|
Consider drug treatment options for moderate-to-severe disease
• Use infliximab in an infusion of 5 mg/kg at 0, 2, and 6 weeks, followed by reinfusion every 8 weeks in patients who are refractory to AZA and MTX
|
- UpToDate
| UpToDate (as of 10/23/2006): |
Close |
From: Infliximab (Remicade®) in Crohn's disease
| (© - subscription required) |
Authors: MacDermott RP et al |
|
|
• We recommend infliximab for patients with moderate to severe Crohn's disease that is refractory to conventional treatment (Grade 1B).
• We recommend retreatment of patients who respond to initial therapy every four- to eight-week interval at 5 mg/kg or 10 mg/kg, depending upon how quickly relapse of the Crohn's disease symptoms occurs (Grade 1B).
• Infliximab should not be used as first line therapy until appropriate clinical trials have been performed. Its value as primary therapy and the long-term effects of infliximab have been able to be fully evaluated.
• A number of adverse events have been described following treatment with infliximab and thus providers and patients should be familiar with the risks and appropriate measures to prevent and monitor for complications.
|
- Patient Information
- Regulatory
Certolizumab
- Description
| Description (as of 4/2007): |
Close |
|
Certolizumab is a PEGylated humanized recombinant monoclonal antibody against tumor necrosis factor.
|
- Clinical Information
- ACP Journal Club (no citations)
- PubMed (one Phase II RCT)
- UpToDate
| UpToDate (as of 12/4/2006): |
Close |
From: Investigational therapies in the medical management of Crohn's disease
| (© - subscription required) |
Authors: Korzenik JR |
|
|
Certolizumab pegol (CDP870) is a humanized monoclonal antibody fragment that neutralizes TNF. It is attached to polyethylene glycol, which increases its plasma half-life and reduces the requirement for frequent dosing, possibly reducing antigenicity as well.
|
- Patient Information
- Regulatory
Natalizumab
- Description
| Description (as of 4/2007): |
Close |
|
Natalizumab is a humanized monoclonal antibody against integrin.
According to the FDA, natalizumab is only availalble through a risk-minimization program with mandatory patient registration and periodic follow-up (details )
|
- Regulatory
- Clinical Information
- ACP Journal Club
- UpToDate
| UpToDate (as of 12/4/2006): |
Close |
From: Investigational therapies in the medical management of Crohn's disease
| (© - subscription required) |
Authors: Korzenik JR |
|
|
An antibody against alpha-4 integrin which had been approved for use in the treatment of multiple sclerosis (natalizumab, Antegren®, Elan Pharmaceuticals and Biogen) has been evaluated for treatment of Crohn's disease]...Several additional case reports have described an association between natalizumab and progressive multifocal leukoencephalopathy. As a result, marketing of the drug was suspended in February 2005 and the future use of this medication remains uncertain.
|
- Patient Information
|
